Skip to main content
Premium Trial:

Request an Annual Quote

Waters Plans New MS Headquarters in UK

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Waters today announced a land-purchase agreement with the Royal Bank of Scotland where it will build a new mass spectrometry headquarter in Wilmslow, Cheshire in the UK.

The new facility, to be situated on the 37-acre Stamford Lodge site, will bring together Waters' mass spec operations located on four separate sites in South Manchester and Altrincham. The facility will include state-of-the-art customer demonstration laboratories, R&D capabilities, and expanded manufacturing capacity.

The new headquarters "will be designed to accelerate the fate of innovation with increased access for the world's scientific thought leaders," said Brian Smith, Waters' vice president of MS business operations, said in a statement.

Final sale of the land is subject to planning and building permission from the Cheshire East Council. It is expected to open in 2013.

The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.